Sarecycline (Seysara®)

Oral Antibiotic
Compare To Other Treatments

The following side effects are expected to occur with the use of sarecycline. Contact your doctor if these symptoms are severe and/or do not go away:

How Common (based on clinical studies)

NauseaUp to 4.6% of all users
HeadacheUp to 2.8% of all users
NasopharyngitisUp to 2.8% of all users
VomitingUp to 2.1% of all users
Vaginal mycotic infectionUp to 0.8% of all users
Vaginal candidiasisUp to 0.6% of all users
DizzinessLess than 1% of all users
PhotosensitivityLess than 1% of all users
Abdominal discomfortUnknown

If you experience any of the following side effects, stop using sarecycline immediately and contact your doctor or get emergency medical care right away:

  • Rash that occurs alongside fever and swollen glands in the neck or elsewhere
  • Trouble breathing or swallowing
  • Reappearance of sore throat, fever, and/or other symptoms of infection
  • Swelling of the eyes, lips, tongue, throat, or face
  • A sudden appearance of swelling and rash (known as hives)
  • Chest pain

Sarecycline may also cause other side effects that are not mentioned here. Contact your doctor if you experience any other troublesome symptoms when using sarecycline.

  1. DailyMed (2023). Sarecycline. [online] Available at: [Accessed 08 Oct. 2023]
  2. Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S, Kempers SE, Kircik LH, Parish JL, Rendon MI, Rich P, Stein-Gold L, Tyring SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. Journal of Drugs in Dermatology. 17(9), 987-996 (2018).
  3. Leyden JJ, Sniukiene V, Berk DR, Kaoukhov A. Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study. Journal of Drugs in Dermatology. 17(3), 333-338 (2018).